(SRRK) Scholar Rock Holding - Overview
Stock: Antibody, Myostatin-Inhibitor, Cancer-Immunotherapy, Neuromuscular, Fibrosis
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 78.5% |
| Relative Tail Risk | -14.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.50 |
| Alpha | -5.17 |
| Character TTM | |
|---|---|
| Beta | 1.278 |
| Beta Downside | 1.499 |
| Drawdowns 3y | |
|---|---|
| Max DD | 65.21% |
| CAGR/Max DD | 0.99 |
Description: SRRK Scholar Rock Holding January 12, 2026
Scholar Rock Holding Corp (NASDAQ:SRRK) is a Cambridge-based biotech that leverages its proprietary platform targeting the TGF-β superfamily to develop monoclonal antibodies that selectively inhibit precursor activation. Its lead assets include Apitegromab, a myostatin-activation inhibitor currently in Phase 3 for spinal muscular atrophy (SMA), and SRK-181, which has finished Phase 1 for checkpoint-inhibitor-resistant cancers. The company’s pipeline spans neuromuscular, cardiometabolic, oncology, fibrosis, and iron-restricted anemia indications, reflecting a broad therapeutic ambition rooted in growth-factor biology.
Key market data (as of Q4 2024) show SRRK’s market capitalization around $350 M, with cash and equivalents of roughly $120 M, giving it ~18 months of runway at its current R&D burn (~$6-7 M per quarter). The global SMA market is projected to exceed $3 B by 2028, while the TGF-β-targeted oncology segment is growing at a CAGR of ~12 % driven by unmet needs in checkpoint-resistance. A primary sector driver is the increasing payer willingness to reimburse disease-modifying therapies for rare neuromuscular disorders, which could materially boost pricing power for Apitegromab if Phase 3 confirms efficacy.
For a deeper, data-driven look at SRRK’s valuation and risk profile, you may find ValueRay’s analyst page useful.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.67 > 0.02 and ΔFCF/TA 38.72 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.67 > 3% & CFO -274.1m > Net Income -353.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.30 > 1.5 & < 3 |
| Outstanding Shares: last quarter (113.7m) vs 12m ago 17.19% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 6.51%; Δ -6.51% > 0%) |
| Interest Coverage Ratio: -81.06 > 6 (EBITDA TTM -351.6m / Interest Expense TTM 4.36m) |
Altman Z'' -15.00
| A: 0.80 (Total Current Assets 390.7m - Total Current Liabilities 62.0m) / Total Assets 411.7m |
| B: -2.94 (Retained Earnings -1.21b / Total Assets 411.7m) |
| C: -1.20 (EBIT TTM -353.3m / Avg Total Assets 295.4m) |
| D: -7.25 (Book Value of Equity -1.21b / Total Liabilities 166.7m) |
| Altman-Z'' Score: -19.99 = D |
What is the price of SRRK shares?
Over the past week, the price has changed by +7.40%, over one month by +15.27%, over three months by +65.35% and over the past year by +16.94%.
Is SRRK a buy, sell or hold?
- StrongBuy: 6
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SRRK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 50.4 | 5.8% |
| Analysts Target Price | 50.4 | 5.8% |
| ValueRay Target Price | 53.5 | 12.4% |
SRRK Fundamental Data Overview February 02, 2026
P/B = 18.7031
Revenue TTM = 0.0 USD
EBIT TTM = -353.3m USD
EBITDA TTM = -351.6m USD
Long Term Debt = 99.6m USD (from longTermDebt, last quarter)
Short Term Debt = 5.33m USD (from shortTermDebt, last quarter)
Debt = 110.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -176.7m USD (from netDebt column, last quarter)
Enterprise Value = 4.26b USD (4.52b + Debt 110.1m - CCE 369.6m)
Interest Coverage Ratio = -81.06 (Ebit TTM -353.3m / Interest Expense TTM 4.36m)
EV/FCF = -15.52x (Enterprise Value 4.26b / FCF TTM -274.6m)
FCF Yield = -6.44% (FCF TTM -274.6m / Enterprise Value 4.26b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 1.63m) / Revenue TTM)
Tobins Q-Ratio = 10.36 (Enterprise Value 4.26b / Total Assets 411.7m)
Interest Expense / Debt = 1.21% (Interest Expense 1.33m / Debt 110.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -279.1m (EBIT -353.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.30 (Total Current Assets 390.7m / Total Current Liabilities 62.0m)
Debt / Equity = 0.45 (Debt 110.1m / totalStockholderEquity, last quarter 245.0m)
Debt / EBITDA = 0.50 (negative EBITDA) (Net Debt -176.7m / EBITDA -351.6m)
Debt / FCF = 0.64 (negative FCF - burning cash) (Net Debt -176.7m / FCF TTM -274.6m)
Total Stockholder Equity = 289.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -119.6% (out of range, set to none)
RoE = -122.0% (Net Income TTM -353.4m / Total Stockholder Equity 289.8m)
RoCE = -90.71% (EBIT -353.3m / Capital Employed (Equity 289.8m + L.T.Debt 99.6m))
RoIC = -79.25% (negative operating profit) (NOPAT -279.1m / Invested Capital 352.1m)
WACC = 10.39% (E(4.52b)/V(4.63b) * Re(10.62%) + D(110.1m)/V(4.63b) * Rd(1.21%) * (1-Tc(0.21)))
Discount Rate = 10.62% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 22.35%
Fair Price DCF = unknown (Cash Flow -274.6m)
EPS Correlation: -8.13 | EPS CAGR: 5.71% | SUE: 4.0 | # QB: 1
Revenue Correlation: -49.47 | Revenue CAGR: -19.16% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.90 | Chg30d=-0.006 | Revisions Net=-3 | Analysts=6
EPS next Year (2026-12-31): EPS=-2.97 | Chg30d=+0.033 | Revisions Net=-2 | Growth EPS=+12.0% | Growth Revenue=+20345.5%